Counterfeit medicines in legitimate supply chains SDCP &PSI Study
Analysis of reports over a five year period – from 2005 to 2010 – indicates that counterfeit medicines increased by 122% while diversion and theft
increased by 66%.
Improvements in surveillance, including detection of security breaches, data
collection, analysis, and dissemination are urgently needed to address the public
health need to combat the global counterfeit medicines trade.
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. The industry’s two million employees discover, develop, and deliver medicines and vaccines that advance global health.
Learn more
Related news and resources
Fee system for regional joint assessment procedures in Africa
This joint position paper covers the perspective from industry on the proposed fee system for regional joint assessment procedures in Africa.
Read more
Pharmacy-mediated substitution for biosimilars
This position paper from IFPMA addresses substitution relating to biosimilars and their reference products at the retail pharmacy level. While this practice has been in place in many countries for generics, for biosimilars, the practice is only emerging.
Read more
Convergence and reliance approaches for advanced therapy medicinal products
Cell, tissue and gene therapies offer significant potential to treat diseases with high unmet medical needs, and consist of human cell and tissue products for medical use and advanced therapy medicinal products (ATMPs). IFPMA shares points to consider when promoting regulatory convergence and reliance approaches for ATMPs.
Read more